Albumin Transfusion in Palliative Care: Evidence-Based Indications

Introduction to Albumin Use in Palliative Care

The American Thoracic Society recommends against the use of intravenous albumin for first-line volume replacement or to increase serum albumin levels in critically ill adult patients, with a Conditional Recommendation and Moderate Certainty of Evidence 1, 2
Hypoalbuminemia in advanced illness represents a marker of disease severity rather than a treatment target, and albumin infusion cannot reverse the underlying causes of low albumin, such as inflammatory cytokines suppressing synthesis and increased transcapillary loss 1, 2
The American College of Chest Physicians suggests that treatment should address the underlying cause of hypoalbuminemia, not the laboratory value itself, emphasizing the futility of correcting low albumin levels alone without treating the primary disease process 1, 2

Albumin administration does not improve survival or functional outcomes in patients with chronic hypoalbuminemia, according to multiple systematic reviews 1, 2
The use of albumin carries significant risks, including fluid overload, hypotension, and anaphylaxis, which can worsen patient comfort and outcomes 1, 2
Albumin is also associated with hemodilution requiring blood transfusion, further contradicting palliative goals 1, 2
The high cost of albumin, approximately $130 per 25g, represents poor resource utilization when it does not improve patient-centered outcomes 1, 2

The only evidence-based indications for albumin use are in cases of cirrhosis-related complications, such as large-volume paracentesis, spontaneous bacterial peritonitis, and hepatorenal syndrome, but these scenarios require active treatment of acute complications and may not align with comfort-focused palliative goals 3, 4
For large-volume paracentesis, administer 8g albumin per liter of ascites removed using 20% or 25% solution to prevent post-paracentesis circulatory dysfunction 3, 4
For spontaneous bacterial peritonitis, give 1.5g/kg within 6 hours of diagnosis, followed by 1g/kg on day 3, which reduces renal dysfunction by 72% and mortality by 47% 4

The American Thoracic Society recommends identifying the reason for considering albumin and assessing if the patient has cirrhosis with acute complication, before deciding on albumin use 1, 2, 3
Evaluate goals of care and consider albumin only if consistent with life-prolonging interventions, and not for comfort-focused care 1, 2, 3
Avoid using serum albumin concentration as an indication for albumin administration, as low albumin is a prognostic marker, not a treatment target 3, 5
Do not assume albumin will reduce edema or improve nutrition, as it does neither effectively and may worsen fluid overload 1, 2, 3